Hematopoietic stem cells from NOD mice exhibit autonomous behavior and a competitive advantage in allogeneic recipients

Blood

Volumn 105, Issue 5, 2005, Pages 2189-2197

  Chilton, Paula M ^a   Rezzoug, Francine ^a   Ratajczak, Mariusz Z ^a   Fugier Vivier, Isabelle ^a   Ratajczak, Janina ^a   Kucia, Magda ^a   Huang, Yiming ^a   Tanner, Michael K ^a   Ildstad, Suzanne T ^a  

^a UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ADHESION; CELL FUNCTION; CHEMOTAXIS; COLONY FORMING UNIT GM; CONTROLLED STUDY; DISEASE RESISTANCE; FEMALE; GENE LOCUS; HEMATOPOIETIC STEM CELL; IN VITRO STUDY; IN VIVO STUDY; ISOGRAFT; MOUSE; NONHUMAN; PRIORITY JOURNAL; STROMA CELL; ALLOTRANSPLANTATION; ANIMAL; COMPARATIVE STUDY; GENETICS; GRAFT SURVIVAL; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INSULIN DEPENDENT DIABETES MELLITUS; NONOBESE DIABETIC MOUSE; PHYSIOLOGY;

ANIMALS; CHEMOTAXIS; DIABETES MELLITUS, TYPE 1; GRAFT SURVIVAL; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; MICE; MICE, INBRED NOD; RECEPTORS, TUMOR NECROSIS FACTOR; TRANSPLANTATION, HOMOLOGOUS;

EID: 14944355273     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-07-2757     Document Type: Article

References (57)

1. Rogner UC, Boitard C, Morin J, Melanitou E, Avner P. Three loci on mouse chromosome 6 influence onset and final incidence of type I diabetes in NOD.C3H congenic strains. Genomics. 2001;74:163-171.
2. Lyons PA, Hancock WW, Denny P, et al. The NOD Idd9 genetic interval influences the pathogenicity of insulitis and contains molecular variants of Cd30, Tnfr2, and Cd137. Immunity. 2000;13:107-115.
3. Fox CJ, Paterson AD, Mortin-Toth SM, Danska JS. Two genetic loci regulate T cell-dependent islet inflammation and drive autoimmune diabetes pathogenesis. Am J Hum Genet. 2000;67:67-81.
4. Penha-Goncalves C, Moule C, Smink LJ, et al. Identification of a structurally distinct CD101 molecule encoded in the 950-kb Idd10 region of NOD mice. Diabetes. 2003;52:1551-1556.
5. Langmuir PB, Bridgett MM, Bothwell AL, Crispe IN. Bone marrow abnormalities in the non-obese diabetic mouse. Int Immunol. 1993;5:169-177.
6. Leiter EH, Serreze DV. Antigen presenting cells and the immunogenetics of autoimmune diabetes in NOD mice. Reg Immunol. 1992;4:263-273.
7. Serreze DV, Gaskins HR, Leiter EH. Defects in the differentiation and function of antigen presenting cells in NOD/Lt mice. J Immunol. 1993;150:2534-2543.
8. Baxter AG, Cooke A. Complement lytic activity has no role in the pathogenesis of autoimmune diabetes in NOD mice. Diabetes. 1993;42:1574-1578.
9. Johansson SE, Hall H, Bjorklund J, Hoglund P. Broadly impaired NK cell function in non-obese diabetic mice is partially restored by NK cell activation in vivo and by IL-12/IL-18 in vitro. Int Immunol. 2004;16:1-11.
10. Lee M, Kim AY, Kang Y. Defects in the differentiation and function of bone marrow-derived dendritic cells in non-obese diabetic mice. J Korean Med Sci. 2000;15:217-223.
11. Serreze DV, Gaedeke JW, Leiter EH. Hematopoietic stem-cell defects underlying abnormal macrophage development and maturation in NOD/Lt mice: defective regulation of cytokine receptors and protein kinase C. Proc Natl Acad Sci U S A. 1993;90:9625-9629.
12. Li H, Kaufman CL, Boggs SS, et al. Mixed allogeneic chimerism induced by a sublethal approach prevents autoimmune diabetes and reverses insulitis in non-obese diabetic (NOD) mice. J Immunol. 1996;156:380-388.
13. Nelson JL, Torrez R, Louie FM, et al. Pre-existing autoimmune disease in patients with longterm survival after allogeneic bone marrow transplantation. J Rheumatol. 1997;24:23-29.
14. Ikehara S, Ohtsuki H, Good RA, et al. Prevention of type I diabetes in nonobese diabetic mice by allogeneic bone marrow transplantation. Proc Natl Acad Sci U S A. 1985;82:7743-7747.
15. Beilhack GF, Scheffold YC, Weissman IL, et al. Purified allogeneic hematopoietic stem cell transplantation blocks diabetes pathogenesis in NOD mice. Diabetes. 2003;52:59-68.
16. LaFace DM, Peck AB. Reciprocal allogeneic bone marrow transplantation between NOD mice and diabetes-nonsusceptible mice associated with transfer and prevention of autoimmune diabetes. Diabetes. 1989;38:894-901.
17. Kaufman CL, Li H, Ildstad ST. Patterns of hemopoietic reconstitution in nonobese diabetic mice: dichotomy of allogeneic resistance versus competitive advantage of disease-resistant marrow. J Immunol. 1997;158:2435-2442.
18. Huang Y, Rezzoug F, Chilton PM, et al. Matching at the MHC class I K locus is essential for longterm engraftment of purified hematopoietic stem cells: a role for host NK cells in regulating HSC engraftment. Blood. 2004;104:873-880.
19. Wright DE, Bowman EP, Wagers AJ, Butcher EC, Weissman IL. Hematopoietic stem cells are uniquely selective in their migratory response to chemokines. J Exp Med. 2002;195:1145-1154.
20. Lapidot T, Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines. and stromal cells. Exp Hematol. 2002;30:973-981.
21. Harrison DE. Competitive repopulation: a new assay for long-term stem cell functional capacity. Blood. 1980;55:77-81.
22. Harrison DE, Astle CM, Lerner C. Number and continuous proliferative pattern of transplanted primitive immunohematopoietic stem cells. Proc Natl Acad Sci U S A. 1988;85:822-826.
23. Domen J, Cheshier SH, Weissman IL. The role of apoptosis in the regulation of hematopoietic stem cells: overexpression of Bcl-2 increases both their number and repopulation potential. J Exp Med. 2000;191:253-264.
24. Kaufman CL, Colson YL, Wren SM, et al. Phenotypic characterization of a novel bone-marrow derived cell that facilitates engraftment of allogeneic bone marrow stem cells. Blood. 1994;84:2436-2446.
25. - cells in whole bone marrow facilitate the engraftment of hematopoietic stem cells across allogeneic barriers. Immunity. 1999;11:579-590.
26. Ploemacher RE, van der Sluijs JP. van Beurden CA, Baert MR, Chan PL. Use of limiting-dilution type long-term marrow cultures in frequency analysis of marrow-repopulating and spleen colony-forming hematopoietic stem cells in the mouse. Blood. 1991;78:2527-2533.
27. de Haan G, Nijhof W, Van Zant G. Mouse strain-dependent changes in frequency and proliferation of hematopoietic stem cells during aging: correlation between lifespan and cycling activity. Blood. 1997;89:1543-1550.
28. de Haan G, Szilvassy SJ, Meyerrose TE, et al. Distinct functional properties of highly purified hematopoietic stem cells from mouse strains differing in stem cell numbers. Blood. 2000;96:1374-1379.
29. Orschell-Traycoff CM, Hiatt K, Dagher RN, et al. Homing and engraftment potential of Sca-1(+)lin(-) cells fractionated on the basis of adhesion molecule expression and position in cell cycle. Blood. 2000;96:1380-1387.
30. Till JE, McCulloch EA. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Rad Res. 1961;14:213-220.
31. Sugiura K, Inaba M, Hisha H, et al. Requirement of major histocompatibility complex-compatible microenvironment for spleen colony formation (CFU-S on day 12 but not on day 8). Stem Cells. 1997;15:461-468.
32. Geiger H, True JM, de Haan G, Van Zant G. Age- and stage-specific regulation patterns in the hematopoietic stem cell hierarchy. Blood. 2001;98:2966-2972.
33. McAleer MA, Reifsnyder P, Palmer SM, et al. Crosses of NOD mice with the related NON strain. A polygenic model for IDDM. Diabetes. 1995;44:1186-1195.
34. Broxmeyer HE, Kim CH, Cooper SH, et al. Effects of CC, CXC, C, and CX3C chemokines on proliferation of myeloid progenitor cells, and insights into SDF-1-induced chemotaxis of progenitors. Ann NY Acad Sci. 1999;872:142-162.
35. Ratajczak MZ, Reca R, Wysoczynski M, et al. Transplantation studies in C3-deficient animals reveal a novel role of the third complement component (C3) in engraftment of bone marrow cells. Leukemia. 2004;18:1482-1490.
36. Frimberger AE, Stering AI, Quesenberry PJ. An in vitro model of hematopoietic stem cell homing demonstrates rapid homing and maintenance of engraftable stem cells. Blood. 2001;98:1012-1018.
37. Reca R, Mastellos D, Majka M, et al. Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem/progenitor cells, and C3a enhances their homing-related responses to SDF-1. Blood. 2003;101:3784-3793.
38. Ratajczak J, Reca R, Kucia M, et al. Mobilization studies in mice deficient in either C3 or C3a receptor (C3aR) reveal a novel role for complement in retention of hematopoietic stem/progenitor cells in bone marrow. Blood. 2004;103:2071-2078.
39. Denny P, Lord CJ, Hill NJ, et al. Mapping of the IDDM locus Idd3 to a 0.35-cM interval containing the interleukin-2 gene. Diabetes. 1997;46:695-700.
40. Lyons PA, Armitage N, Argentina F, et al. Congenic mapping of the type 1 diabetes locus, Idd3, to a 780-kb region of mouse chromosome 3: identification of a candidate segment of ancestral DNA by haplotype mapping. Genome Res. 2000;10:446-453.
41. Podolin PL, Wilusz MB, Cubbon RM, et al. Differential glycosylation of interleukin 2, the molecular basis for the NOD Idd3 type 1 diabetes gene? Cytokine. 2000;12:477-482.
42. Lyons PA, Armitage N, Lord CJ, et al. Mapping by genetic interaction: high-resolution congenic mapping of the type 1 diabetes loci Idd10 and Idd18 in the NOD mouse. Diabetes. 2001;50:2633-2637.
43. Podolin PL, Denny P, Armitage N, et al. Localization of two insulin-dependent diabetes (Idd) genes to the Idd10 region on mouse chromosome 3. Mamm Genome. 1998;9:283-286.
44. Hill NJ, Lyons PA, Armitage N, et al. NOD Idd5 locus controls insulitis and diabetes and overlaps the orthologous CTLA4/IDDM12 and NRAMP1 loci in humans. Diabetes. 2000;49:1744-1747.
45. Mouse Genome Informatics, The Jackson Laboratory. Mouse Genome Database (MGD). http://www.informatics.jax.org. Accessed November 2003.
46. Hashimoto F, Sugiura K, Inoue K, Ikehara S. Major histocompatibility complex restriction between hematopoietic stem cells and stromal cells in vivo. Blood. 1997;89:49-54.
47. Takao F, Yasumizu R, Than S, et al. Development of insulin-dependent diabetes mellitus in [(NOD + BALB/c) → NOD] mixed allogeneic bone marrow chimeras. Immunobiology. 1995;194:376-389.
48. Kawamura M, Hisha H, Li Y, Fukuhara S, Ikehara S. Distinct qualitative differences between normal and abnormal hemopoietic stem cells in vivo and in vitro. Stem Cells. 1997;15:56-62.
49. Bachar-Lustig E, Rachamim N, Li HW, Lan F, Reisner Y. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med. 1995;1:1268-1273.
50. - cells and nonalloreactive T cells. Transplant Proc. 1998;30:4007-4008.
51. + progenitor cells. J Hematother Stem Cell Res. 2002;11:895-903.
52. Chakrabarty S, Nagata M, Yasuda H, et al. Critical roles of CD30/CD30L interactions in murine autoimmune diabetes. Clin Exp Immunol. 2003;133:318-325.
53. Sytwu HK, Lin WD, Roffler SR, et al. Anti-4-1BB-based immunotherapy for autoimmune diabetes: lessons from a transgenic non-obese diabetic (NOD) model. J Autoimmun. 2003;21:247-254.
54. + early erythroid progenitors are resistant to several erythropoietic 'inhibitory' cytokines: role of FLIP. Brit J Haematol. 2003;123:160-169.
55. + stem/progenitor cells to bone marrow. Blood. 2004;103:2981-2989.
56. Jackson Laboratory. JAX/MICE: Setting the gold standard for genetic purity. Bar Harbor, ME: JAX Research Systems; 2003.
57. Trowsdale J, Campbell RD. Mouse MHC genes and products, in: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, and Strober W, eds. Current protocols in immunology. Hoboken, NJ: John Wiley & Sons; 2001:A1.L.